Skip to main
  1. Stocks
  2. Perspective Therapeutics Inc
  3. Forecast
CATX

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics is attractive because its Lead-212 platform offers a differentiated radiopharmaceutical mechanism with high tumor-killing potency and potentially lower off-target toxicity, while the pipeline spans multiple cancer settings that broaden commercial optionality. Recent data from bamzireotide navoxetan in SSTR2+ NETs showed 37%/47% ORR, 92%/100% DCR, and 75% pooled 18-month PFS across Cohorts 1-3, and lapemelanotide zapixetar also showed a 25% confirmed response rate with no DLTs or treatment-related discontinuations. The company ended 3Q26 with about $202MM in cash and investments, expects funding into 2028, and has key catalysts ahead in 1Q27, 2027, and early 2027 manufacturing completion that could further de-risk the story.

Bears say

Perspective Therapeutics is viewed negatively because the company faces a broad set of fundamental risks, including product commercialization and supply chain exposure, concentration risk, clinical and regulatory uncertainty, liquidity pressure, and partnership, legal, intellectual property, macroeconomic, and geopolitical risk. Its valuation is especially vulnerable to poorer-than-expected clinical data, since adverse trial outcomes could materially weaken the market potential and economics of its product candidates. Longer term, intensifying competition and the possibility of unfavorable reimbursement or slow adoption of marketed products could further impair commercial execution and delay any path to durable value creation.

CATX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

CATX Analyst Forecast & Price Prediction

Get the latest CATX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CATX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Buy based on their latest research and market trends.

According to 10 analysts, CATX has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


CATX Analyst Forecast & Price Prediction

Get the latest CATX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CATX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CATX stock data and trends